CI

At a glance

ClinicalIndex Comparison Record
Phase 2Active· 120 enrolled
Drug / intervention
Hypofractionated Radiation Therapy +3 moreradiation
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04562480
NCT04562480Phase 2Active

A Phase II Study of Hypofractionated Pre-Operative Radiation Therapy for Localized, Resectable Soft Tissue Sarcoma of the Extremity and Superficial Trunk

Mayo Clinic·interventional·Posted Sep 24, 2020·Updated Feb 4, 2026

In Brief

A Phase 2 clinical trial evaluating Hypofractionated Radiation Therapy, Quality-of-Life Assessment, and 2 other interventions for Resectable Soft Tissue Sarcoma and 4 related conditions. Active but no longer recruiting, targeting 120 participants across 3 sites.

Detailed Summary

This phase II trial investigates the effects of hypofractionated radiation therapy before surgery on wound complications associated with surgery in treating patients with soft tissue sarcoma of the extremity (arms, hands, legs or feet) and superficial trunk that has not spread to other parts of the body (localized) and can be removed by surgery (resectable). Hypofractionated is a shorter radiation therapy treatment length (fewer radiation treatment days) and administers the total radiation dose as larger daily doses, compared to conventionally fractionated therapy.

Study Details

Timeline

Phase 2Active
2021202220232024202520262027202820292030
First PostedSep 24, 2020
Enrollment StartNov 30, 2020
Primary CompletionOct 31, 2024
Study CompletionOct 31, 2029
TodayJul 2, 2026
Enrollment to primary: 3.9 yearsPosted 5.8 years ago

Interventions

Hypofractionated Radiation Therapyradiation

Undergo hypofractionated radiation therapy

Quality-of-Life Assessmentother

Ancillary studies

Questionnaire Administrationother

Ancillary studies

Resectionprocedure

Undergo surgical resection